ASH 2017: Mixed results for new NHL therapies
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.
Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.
Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.
Interviewer: Esther Drain Dr Toby Eyre (Oxford), Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell therapy and the first EZH2 inhibitor, tazemetostat, in… read more.
By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.
The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.
Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.
Dr Andrei Shustov (University of Washington School of Medicine, Seattle, USA) summarises the advances in T-Cell lymphoma therapy at ASH 2016, including long term data in PTCL and ALCL…. read more.
Article written by Tom Collins. Interview by Esther Drain. With technology that allows clinicians to determine minimal residual disease negativity down to the 10-6 level, the word “cure” hangs… read more.
by Christine Clark ISHL 2016 Professor Joseph Connors (Vancouver) speaks about the session at ISHL10 where a world view of the management of Hodgkin lymphoma was discussed. There… read more.
Professor Mohamad Mohty (Paris), Professor Sagar Lonial (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.